Selisistat

Selisistat is a first-in-class, orally available small molecule that acts as a potent and selective inhibitor of the SIRT1 protein (silent information regulator 1), a NAD+-dependent deacetylase enzyme. It exhibits over 200-fold selectivity for SIRT1 compared to other sirtuin family members such as SIRT2 and SIRT3. Selisistat was originally discovered by Elixir Pharmaceuticals and has been developed by AOP Orphan Pharmaceuticals and Siena Biotech primarily as a disease-modifying therapy for Huntington's disease. The drug inhibits the deacetylation activity of SIRT1 on various substrates including p53 tumor suppressor protein, thereby modulating gene expression involved in cell survival and stress responses. Selisistat has demonstrated neuroprotective effects in preclinical models of Huntington’s disease but did not show significant clinical efficacy in phase II trials; development for this indication appears to have been discontinued[1][3][4][5][6].

Brand names

Selisistat

Other names

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide